
- /
- Supported exchanges
- / US
- / RCDTF.PINK
Recordati Industria Chimica e Farmaceutica S.p.A (RCDTF PINK) stock market data APIs
Recordati Industria Chimica e Farmaceutica S.p.A Financial Data Overview
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops REC 0545 for acute decompensation in maple syrup urine diseases; Isturia for endogenous Cushing's syndrome; Cystadrops for corneal cystine crystal deposits; Carbaglu for hyperammonemia due to n-acetyl glutamate synthase deficiency; Qarziba for neuroblastoma patients and patients with relapsed or refractory neuroblastoma; and Fortivda for renal cell carcinoma. It also develops Sylvant for idiopathic multicentric castleman diseases; Caphosol for oral mucositis; ENJAYMO for hemolysis in adults with cold agglutinin disease; Zanidip, Zanipress, and Logimax for hypertension; Urorec and Avodart for symptoms of benign prostatic hyperplasia; and Livazo for dyslipidemia; Seloken for angina pectoris, myocardial infarction and cardiac rhythm disorders, as well as hypertension and functional heart disorders. In addition, the company offers Procto-Glyveno for internal and external hemorrhoids; Polydexa, Isofra, and Otofa for ear, nose and throat infections; Tergynan, an anti-infective for gynecological infections; CitraFleet and Phosphosoda as bowel cleansers; Lomexin for gynecological and dermatological infections; Hexaspray, a throat spray; Magnesio Supremo, a dietary supplement; Reaglia for schizophrenia; Eligard for hormone-dependent prostate cancer; REC 0559 for neurotrophic keratitis; and pasireotide in Phase II trial for patients with post-bariatric hypoglycemia, as well as other products. Recordati Industria Chimica e Farmaceutica S.p.A. was founded in 1926 and is headquartered in Milan, Italy.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Recordati Industria Chimica e Farmaceutica S.p.A data using free add-ons & libraries
Get Recordati Industria Chimica e Farmaceutica S.p.A Fundamental Data
Recordati Industria Chimica e Farmaceutica S.p.A Fundamental data includes:
- Net Revenue: 2 414 M
- EBITDA: 867 M
- Earnings Per Share: 2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get Recordati Industria Chimica e Farmaceutica S.p.A Earnings data
What’s included:
- Latest Release: 2025-05-07
- EPS/Forecast: NaN
Get Recordati Industria Chimica e Farmaceutica S.p.A End-of-day data
EOD Historical Data package for
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Recordati Industria Chimica e Farmaceutica S.p.A News

European Stocks That May Be Trading Below Estimated Value In June 2025
As European markets navigate the complexities of geopolitical tensions and economic shifts, indices such as the STOXX Europe 600 have experienced declines, reflecting broader concerns. In this environ...


Amarin inks licensing deal with Recordati for lead drug Vazkepa
[Collaboration concept in word tag cloud] rafal_olechowski Amarin Corporation (NASDAQ:AMRN [https://seekingalpha.com/symbol/AMRN]) traded ~7% higher in the premarket on Tuesday after the company anno...

RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE
Recordati RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE Vazkepa® supported by strong clinical data package and expected to contribute ...

European Stock Picks That May Be Undervalued In May 2025
As of mid-May 2025, European markets have shown resilience, with the pan-European STOXX Europe 600 Index climbing 2.10% following a positive shift in global trade relations and an uptick in economic a...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.